Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
October 27, 2022 09:04 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Global Research Antibodies Market Analysis Report 2022: A $2.21 Billion Market by 2030 - Expansion in Neurobiology and Stem Cell Research to Propel Growth
October 24, 2022 04:23 ET
|
Research and Markets
Dublin, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The "Research Antibodies Market Size, Share & Trends Analysis Report by Product (Primary, Secondary), by Type, by Technology, by Source, by Application,...
Cancer Monoclonal Antibodies Market Report 2022: Featuring AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Merck & More
October 19, 2022 08:08 ET
|
Research and Markets
Dublin, Oct. 19, 2022 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Intravenous Immunoglobulin Global Market Report 2022: Growing Pharmaceutical Industry Presents Opportunities
October 12, 2022 06:03 ET
|
Research and Markets
Dublin, Oct. 12, 2022 (GLOBE NEWSWIRE) -- The "Intravenous Immunoglobulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Application, Distribution Channel, End User, and...
Global Immunohistochemistry Market to Surpass US$ 2,448.93 Million by 2030, Says Coherent Market Insights (CMI)
October 10, 2022 09:10 ET
|
CMI
Seattle, Oct. 10, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immunohistochemistry market is estimated to be valued at US$ 1,463.69 million in 2022 and expected to...
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
October 04, 2022 08:45 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Global Monoclonal Antibodies (mAbs) Market Analysis Report 2022: A Projected $494.53 Billion Market by 2030
September 30, 2022 05:58 ET
|
Research and Markets
Dublin, Sept. 30, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies Market Size, Share & Trends Analysis Report by Source Type (Chimeric, Murine, Humanized, Human), by Production Type (In...
Global Antibody Therapeutics Market Analysis Report 2022-2027 - Key Manufacturers are Striving to Reduce In-house Operations to Leverage the Capabilities of CDMOs
September 26, 2022 04:38 ET
|
Research and Markets
Dublin, Sept. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Antibody Therapeutics Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This research service offers an...
Dyadic to Present at Upcoming Industry and Investor Events in September
September 08, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Monoclonal Antibodies (MAbS) Global Market Report 2022: Increasing Product Launches and Regulatory Support for the Treatment of Rare Diseases to Fuel Future Growth
August 31, 2022 04:28 ET
|
Research and Markets
Dublin, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies (MAbS) Global Market Report 2022: By Source, By Application, By End-User" report has been added to ResearchAndMarkets.com's...